Bacteriophage compositions for treating pseudomonas infection
AssigneeArmata Pharmaceuticals, Inc.
InventorsSebastien Lemire, Stacey Lynn Kolar, Brian C. Varnum
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to bacteriophages and compositions capable of infecting and killing Pseudomonas, and use of the same for treating Pseudomonas, e.g. Pseudomonas aeruginosa, bacterial infections.
Claims207
A bacteriophage composition comprising one or more bacteriophages comprising a polynucleotide sequence selected from the polynucleotide sequence of SEQ ID NO:
- 1, a polynucleotide sequence of SEQ ID NO:
- 2, a polynucleotide sequence of SEQ ID NO:
- 3, a polynucleotide sequence with at least 90% identity to SEQ ID NO:
- 1, a polynucleotide sequence with at least 90% identity to SEQ ID NO:
- 2, and/or a polynucleotide sequence with at least 90% identity to SEQ ID NO:
- 3.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
The isolated, purified bacteriophage of claim 13, comprising a polynucleotide sequence of SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, SEQ ID NO:
- 12, SEQ ID NO:
- 13, SEQ ID NO:
- 14, SEQ ID NO:
- 15, SEQ ID NO:
- 16, SEQ ID NO:
- 17, SEQ ID NO:
- 18, SEQ ID NO:
- 19, SEQ ID NO:
- 20, SEQ ID NO:
- 21, or SEQ ID NO:
- 22.
An isolated, purified bacteriophage comprising a polynucleotide sequence with at least 90% identity to SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, SEQ ID NO:
- 12, SEQ ID NO:
- 13, SEQ ID NO:
- 14, SEQ ID NO:
- 15, SEQ ID NO:
- 16, SEQ ID NO:
- 17, SEQ ID NO:
- 18, SEQ ID NO:
- 19, SEQ ID NO:
- 20, SEQ ID NO:
- 21, or SEQ ID NO:
- 22.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A bacteriophage composition comprising two or more bacteriophages, wherein at least one of the bacteriophages comprises a polynucleotide sequence having at least 90% identity to a sequence selected from the polynucleotide sequence of SEQ ID NO:
- 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, and 22;
- and wherein at least one other bacteriophage infects a Pseudomonas bacterium.
(canceled)
(canceled)
(canceled)
(canceled)
A bacteriophage composition comprising one or more bacteriophages comprising a polynucleotide sequence having 90% to 100% identity to a sequence selected from the polynucleotide sequence of SEQ ID NO:
- 1, a polynucleotide sequence of SEQ ID NO:
- 2, a polynucleotide sequence of SEQ ID NO:
- 3, a polynucleotide sequence of SEQ ID NO:
- 4, a polynucleotide sequence of SEQ ID NO:
- 5, a polynucleotide sequence of SEQ ID NO:
- 6, a polynucleotide sequence of SEQ ID NO:
- 7, a polynucleotide sequence of SEQ ID NO:
- 8, a polynucleotide sequence of SEQ ID NO:
- 9, a polynucleotide sequence of SEQ ID NO:
- 10, a polynucleotide sequence of SEQ ID NO:
- 11, a polynucleotide sequence of SEQ ID NO:
- 12, a polynucleotide sequence of SEQ ID NO:
- 13, a polynucleotide sequence of SEQ ID NO:
- 14, a polynucleotide sequence of SEQ ID NO:
- 15, a polynucleotide sequence of SEQ ID NO:
- 16, a polynucleotide sequence of SEQ ID NO:
- 17, a polynucleotide sequence of SEQ ID NO:
- 18, a polynucleotide sequence of SEQ ID NO:
- 19, a polynucleotide sequence of SEQ ID NO:
- 20, a polynucleotide sequence of SEQ ID NO:
- 21, and a polynucleotide sequence of SEQ ID NO:
- 22.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A bacteriophage composition comprising, consisting essentially of, or consisting of a bacteriophage comprising a polynucleotide sequence of SEQ ID NO:
- 1, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO:
- 2, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO:
- 3, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO:
- 4, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO:
- 5, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO:
- 6, and one or more bacteriophages selected from a bacteriophage comprising a polynucleotide sequence with 90%-100% identity to a sequence of SEQ ID NO:
- 4, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO:
- 5, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO:
- 6, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO:
- 7, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO:
- 8, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO:
- 9, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO:
- 10, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO:
- 11, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO:
- 12, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO:
- 13, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO:
- 14, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO:
- 15, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO:
- 16, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO:
- 17, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO:
- 18, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO:
- 19, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO:
- 20, a bacteriophage comprising a polynucleotide sequence of SEQ ID NO:
- 21, and/or a bacteriophage comprising a polynucleotide sequence of SEQ ID NO:
- 22.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of treating a subject with a bacterial infection comprising selecting a bacteriophage based upon resistance to sputum inactivation and administering said bacteriophage to the subject, wherein the bacteriophage is selected from a bacteriophage comprising a polynucleotide sequence having at least 90% identity to a polynucleotide sequence selected from SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, SEQ ID NO:
- 12, SEQ ID NO:
- 13, SEQ ID NO:
- 14, SEQ ID NO:
- 15, SEQ ID NO:
- 16, SEQ ID NO:
- 17, SEQ ID NO:
- 18, SEQ ID NO:
- 19, SEQ ID NO:
- 20, SEQ ID NO:
- 21, and/or SEQ ID NO:
- 22.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A bacterial host manufacturing strain comprising a bacteriophage selected from a bacteriophage comprising a polynucleotide sequence having 85%-100% identity to a sequence of SEQ ID NO:
- 1-22.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.